VNDA +.39 to 12.95, up 200%+ in the past 10 weeks. It does seem a bit pricey with a market cap near $400M if the potential Tasimelteon drug user base is just 65k domestically. Yet the company believes the worldwide market potential is $500M per year ??? Will health insurance cover costs for this presumably expensive drug that may be no better than a sleeping pill ? Hard to reconcile those figures which are cited in this article -
Although non-24-hour sleep-wake disorder can affect sighted people also, it is mostly seen in people who are totally blind and who don't have sensitivity to light. It is estimated that 50% of totally blind people in the U.S., or approximately 65,000 people, suffer from this sleep condition. Vanda estimates the total worldwide market potential of Tasimelteon in the indication of non-24-hour sleep-wake disorder at $500 million.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.